These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 15780701

  • 1. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase.
    Yonkers KA, Pearlstein T, Fayyad R, Gillespie JA.
    J Affect Disord; 2005 Apr; 85(3):317-21. PubMed ID: 15780701
    [Abstract] [Full Text] [Related]

  • 2. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
    Miner C, Brown E, McCray S, Gonzales J, Wohlreich M.
    Clin Ther; 2002 Mar; 24(3):417-33. PubMed ID: 11952025
    [Abstract] [Full Text] [Related]

  • 3. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.
    Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M.
    JAMA Psychiatry; 2015 Oct; 72(10):1037-44. PubMed ID: 26351969
    [Abstract] [Full Text] [Related]

  • 4. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder.
    Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA.
    J Affect Disord; 2005 Apr; 85(3):275-82. PubMed ID: 15780697
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
    Freeman EW.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder.
    Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L.
    Obstet Gynecol; 2002 Dec; 100(6):1219-29. PubMed ID: 12468166
    [Abstract] [Full Text] [Related]

  • 7. Variable dosing of sertraline for premenstrual exacerbation of depression: a pilot study.
    Miller MN, Newell CL, Miller BE, Frizzell PG, Kayser RA, Ferslew KE.
    J Womens Health (Larchmt); 2008 Dec; 17(6):993-7. PubMed ID: 18681820
    [Abstract] [Full Text] [Related]

  • 8. Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols.
    Wu KY, Liu CY, Hsiao MC.
    Psychiatry Clin Neurosci; 2008 Feb; 62(1):109-14. PubMed ID: 18289149
    [Abstract] [Full Text] [Related]

  • 9. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C, Olivieri L, Di Loreto G, Dionisio P.
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [Abstract] [Full Text] [Related]

  • 10. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study.
    Berger CP, Presser B.
    Obstet Gynecol; 1994 Sep; 84(3):379-85. PubMed ID: 8058235
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder.
    Cohen LS, Soares CN, Lyster A, Cassano P, Brandes M, Leblanc GA.
    J Clin Psychopharmacol; 2004 Oct; 24(5):540-3. PubMed ID: 15349012
    [Abstract] [Full Text] [Related]

  • 12. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome.
    Halbreich U, Smoller JW.
    J Clin Psychiatry; 1997 Sep; 58(9):399-402. PubMed ID: 9378691
    [Abstract] [Full Text] [Related]

  • 13. Proton magnetic resonance spectroscopy measurement of brain glutamate levels in premenstrual dysphoric disorder.
    Batra NA, Seres-Mailo J, Hanstock C, Seres P, Khudabux J, Bellavance F, Baker G, Allen P, Tibbo P, Hui E, Le Melledo JM.
    Biol Psychiatry; 2008 Jun 15; 63(12):1178-84. PubMed ID: 18061146
    [Abstract] [Full Text] [Related]

  • 14. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder.
    Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H.
    J Clin Psychiatry; 2005 Jun 15; 66(6):769-73. PubMed ID: 15960573
    [Abstract] [Full Text] [Related]

  • 15. Long-term fluoxetine treatment of late luteal phase dysphoric disorder.
    Pearlstein TB, Stone AB.
    J Clin Psychiatry; 1994 Aug 15; 55(8):332-5. PubMed ID: 8071300
    [Abstract] [Full Text] [Related]

  • 16. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder.
    Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S.
    Am J Psychiatry; 2004 Feb 15; 161(2):343-51. PubMed ID: 14754784
    [Abstract] [Full Text] [Related]

  • 17. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Feb 15; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 18. Menstrually related symptom changes in women with treatment-responsive bipolar disorder.
    Karadag F, Akdeniz F, Erten E, Pirildar S, Yucel B, Polat A, Atmaca M.
    Bipolar Disord; 2004 Jun 15; 6(3):253-9. PubMed ID: 15117404
    [Abstract] [Full Text] [Related]

  • 19. Symptoms of depression in late luteal phase dysphoric disorder: a variant of mood disorder?
    De Ronchi D, Ujkaj M, Boaron F, Muro A, Piselli M, Quartesan R.
    J Affect Disord; 2005 Jun 15; 86(2-3):169-74. PubMed ID: 15935236
    [Abstract] [Full Text] [Related]

  • 20. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study.
    Freeman EW, Sondheimer SJ, Rickels K.
    Psychopharmacol Bull; 1997 Jun 15; 33(2):303-9. PubMed ID: 9230648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.